Codiak BioSciences Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Codiak BioSciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11038
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Codiak BioSciences Inc (Codiak BioSciences) is an exosome therapeutics company that focuses on the development of proprietary pipeline of targeted medicines for diseases with unmet medical needs. The company’s platform capitalizes on exosomes, which are nanometer-sized membrane sacs that delivers proteins, lipids, nucleic acids and small molecules to various cell types. Codiak defines and engineers exosomes with single and multiple payloads against specific intracellular targets. The company also has rights to a novel investigational drug candidate for the treatment of pancreatic cancer, from The University of Texas, MD Anderson Cancer Center. Codiak BioSciences is headquartered in Cambridge, Massachusetts, the US.

Codiak BioSciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Codiak BioSciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Codiak BioSciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Codiak BioSciences Raises USD76.5 Million in Series C Financing 11
Codiak BioSciences Raises USD61 Million in Series B Financing 13
Codiak BioSciences Raises USD31 Million in Series A Financing 15
Licensing Agreements 17
Codiak BioSciences Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 17
Codiak BioSciences Inc – Key Competitors 18
Codiak BioSciences Inc – Key Employees 19
Codiak BioSciences Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Jun 04, 2018: Codiak BioSciences Appoints Richard Brudnick As Chief Business Officer And Head Of Strategy 21
Product News 22
Jun 07, 2017: Potential Therapeutic Use of Exosomes Reported in NATURE 22
Other Significant Developments 23
Nov 06, 2018: Codiak BioSciences presents first data on exoSTING – a novel engineered exosome therapeutic targeting checkpoint refractory tumors at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Codiak BioSciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Codiak BioSciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Codiak BioSciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Codiak BioSciences Raises USD76.5 Million in Series C Financing 11
Codiak BioSciences Raises USD61 Million in Series B Financing 13
Codiak BioSciences Raises USD31 Million in Series A Financing 15
Codiak BioSciences Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 17
Codiak BioSciences Inc, Key Competitors 18
Codiak BioSciences Inc, Key Employees 19

List of Figures
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Codiak BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Codiak BioSciences Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Codiak BioSciences Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LEO Pharma AS-医療機器分野:企業M&A・提携分析
    Summary LEO Pharma A/S (LEO Pharma) is a research-based pharmaceutical company. It undertakes the discovery, development, manufacture and commercialization of pharmaceuticals in the therapeutic areas dermatology and thrombosis. The company focuses on the treatment of diseases such as psoriasis, ecze …
  • Aitken Spence Hotel Holdings PLC:企業の戦略・SWOT・財務情報
    Aitken Spence Hotel Holdings PLC - Strategy, SWOT and Corporate Finance Report Summary Aitken Spence Hotel Holdings PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Flex Pharma Inc (FLKS):製薬・医療:M&Aディール及び事業提携情報
    Summary Flex Pharma Inc (Flex Pharma) is a clinical-stage biotechnology company that offers discovery and development of innovative and proprietary treatments for muscle cramps, spasms and spasticity connected to the severe neurological diseases of ALS, MS, fibromyalgia, hypomagnesemia, hypocalcemia …
  • Neurosigma Inc:企業の製品パイプライン分析2018
    Summary Neurosigma Inc (Neurosigma) is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. The company offers treatments for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stre …
  • F. Hoffmann-La Roche Ltd:戦略・SWOT・企業財務分析
    F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report Summary F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • ResApp Health Ltd (RAP):企業の財務・戦略的SWOT分析
    ResApp Health Ltd (RAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Itochu Chemical Frontier Corp-製薬・医療分野:企業M&A・提携分析
    Summary Itochu Chemical Frontier Corp (ICF), formerly Ando Kaseihin KK, a subsidiary of Itochu Corporation, is a chemical company that manufactures and markets chemical products. The company operates in intermediate chemical division, silicone and adhesive division, osaka and nagoya division, perfor …
  • Cytogel Pharma LLC-製薬・医療分野:企業M&A・提携分析
    Summary Cytogel Pharma LLC (Cytogel Pharma) is a biopharmaceutical development company that provides platform technologies and product candidates. The company offers novel analgesic product candidates and polymer and hydrogel drug delivery platform technologies. Its analgesic product candidates offe …
  • Veikkaus Oy:企業の戦略的SWOT分析
    Veikkaus Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Sogefi S.p.A:企業の戦略・SWOT・財務情報
    Sogefi S.p.A - Strategy, SWOT and Corporate Finance Report Summary Sogefi S.p.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Akebia Therapeutics Inc (AKBA):製薬・医療:M&Aディール及び事業提携情報
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …
  • Town Centre Securities Plc:企業の戦略・SWOT・財務情報
    Town Centre Securities Plc - Strategy, SWOT and Corporate Finance Report Summary Town Centre Securities Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Copan Italia SpA:医療機器:M&Aディール及び事業提携情報
    Summary Copan Italia SpA (Copan Italia) is a medical equipment provider that offers lab consumables and diagnostic products. The company’s products include clinical products, lab automation products, and genetics, forensics, and lab consumable products, among others. Its lab automation products allo …
  • GW Pharmaceuticals Plc (GWP):企業の財務・戦略的SWOT分析
    GW Pharmaceuticals Plc (GWP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Ormat Technologies Inc (ORA):企業の財務・戦略的SWOT分析
    Ormat Technologies Inc (ORA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Duke Energy Corporation:発電所・企業SWOT分析
    Duke Energy Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Sypris Solutions Inc (SYPR):企業の財務・戦略的SWOT分析
    Sypris Solutions Inc (SYPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • BioStem Technologies Inc (BSEM):製薬・医療:M&Aディール及び事業提携情報
    Summary BioStem Technologies Inc. (BioStem Technologies), formerly Caribbean International Holdings Inc., is a life sciences company that discovers, develops and manufactures pharmaceuticals and regenerative medicines. Through its subsidiaries, the company discovers, develops, produces and commercia …
  • Noor Takaful:企業の戦略・SWOT・財務分析
    Noor Takaful - Strategy, SWOT and Corporate Finance Report Summary Noor Takaful - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Swiss Post Ltd:企業の戦略的SWOT分析
    Swiss Post Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆